Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine
Completed
Allergan
Phase 3
2016-07-22
This study will evaluate the efficacy, safety, and tolerability of 2 doses of ubrogepant (50
and 100 mg) compared to placebo for the acute treatment of a single migraine attack.
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
Completed
Allergan
Phase 3
2016-08-26
This study will evaluate the efficacy, safety, and tolerability of 2 doses of ubrogepant (25
and 50 mg) compared to placebo for the acute treatment of a single migraine attack.
An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine
Completed
Allergan
Phase 3
2016-09-13
This study will evaluate the long-term safety and tolerability of intermittent treatment with
ubrogepant for the acute treatment of migraine over 1 year.
Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine
Completed
Allergan
Phase 1
2019-09-26
This study will evaluate the potential for a pharmacokinetic (PK) interaction and provide
safety and tolerability information when ubrogepant and erenumab or ubrogepant and
galcanezumab are co-administered.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
